Discovery Shows How to Prevent Fatal Heart Inflammation from Cancer Immunotherapy

Scientists at Cincinnati Children's have discovered a way to dramatically reduce the risk of fatal heart inflammation caused by immune checkpoint inhibitor cancer treatments. Details were published Feb 20, 2026, in the Journal of Experimental Medicine.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enabling the immune system to recognize and attack tumor cells. Drugs like Keytruda and Opdivo have provided hope and extended survival for many facing metastatic cancers. However, in about 2% of all cancer patients receiving ICIs, the treatments can cause myocarditis—an inflammation of heart muscle. About half of these patients die from this complication, even if they survive their cancer.

The research team engineered a new mouse model that accurately mimics immune checkpoint inhibitor-induced myocarditis. Through a series of advanced experiments, the team pinpointed a key driver of the complication: CD8 T cell-derived tumor necrosis factor (TNF).

The study unveiled that the myocarditis stems not from exhaustion of tumor-specific T cells, as previously speculated, but from the generation of autoreactive CD8+ T cells targeting cardiac myocytes. Checkpoint inhibitors allow TNF signaling to trigger CD8 T-cells that are specific to antigens on cardiac myocytes, which in turn leads to life-threatening arrhythmias.

The research underscores the critical role of TNF signaling through its receptor TNFR2 in cardiac myocytes to perpetuate myocarditis. The team went on to show, in mice, that blocking TNF signaling specifically through the TNFR2 gene product prevented the inflammatory cycle from starting in the heart. This targeted inhibition arrested the inflammatory cascade responsible for myocarditis without diminishing the anti-tumor immune response.

"This study makes a very important discovery that shows how to uncouple anti-tumor efficacy from cardiac toxicity. These findings have major implications for treating or avoiding immune related adverse events in cancer patients receiving immune checkpoint blockade," says the director of the Division of Immunology at Cincinnati Children's, who served as co-corresponding author on the study.

The director of the Division of Molecular Cardiovascular Biology, who served as co-corresponding author, stated: "We used a targeted TNF blockade method to prevent this cycle in our mouse models. If these results can be replicated in humans, TNF blockade should prevent cardiac toxicity without compromising the anti-tumor benefits of ICIs."

An MD-Ph.D. student served as first author and led the research work.

Immune checkpoint inhibitors work by cutting off signals from "checkpoint" proteins that cancer cells use to hide from the immune system. This allows the body's T cells to recognize and destroy tumor cells. Since 2011, when the first drug (Yervoy) was approved in the U.S. for treating metastatic melanoma, this form of treatment has revolutionized outcomes for many types of cancer. The inventors—James Allison and Tasuku Honjo—received the Nobel Prize in Medicine in 2018 for their discovery.

More research is needed to determine if a narrowly focused TNF inhibitor would be safe for human use, and how long a patient might need to take such a drug. TNFR2-specific antibodies remain in development stages. The team also wants to determine whether similar approaches can also prevent immune-related adverse events affecting other organs.

Cincinnati Children's co-authors also included multiple researchers. These core services also contributed to the study: the Veterinary Services Facility, Research Flow Cytometry Core, Transgenic Animal and Genome Editing Facility, Integrated Pathology Research Facility, and the Bio-Imaging and Analysis Facility.